BridgeBio to Participate in September Investor Conferences
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) announced that its management team will participate in several healthcare investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Morgan Stanley, and Bernstein in Boston and New York on dates between September 9 and September 23.
Live webcasts of the fireside chats will be available via the Investors “Events and Presentations” page on BridgeBio’s website, with replays accessible for 90 days. BridgeBio describes itself as a commercial-stage biopharmaceutical company developing medicines for genetic conditions using a decentralized hub-and-spoke model.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 31 | Government access agreement | Positive | -0.0% | Agreement aimed to expand Medicaid access and lower medicine costs for American patients. |
| Aug 26 | Phase 3b/4 dosing | Positive | -1.3% | First participant received treatment in long-term acoramidis ATTR-CM study. |
| Aug 24 | Acoramidis data presentation | Positive | -0.5% | Company announced new open-label extension analyses and additional conference presentations. |
| Aug 14 | Secondary offering pricing | Negative | -1.7% | Existing shareholder priced a 5,000,000-share secondary offering without company proceeds. |
| Aug 13 | Secondary offering launch | Negative | -1.7% | Existing shareholder launched a 5,000,000-share offering under an automatic shelf registration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or informational announcements generally diverged from negative price reactions, while both recent secondary-offering events aligned with declines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
- 21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT
- 2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT
- Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT
- Bernstein Insights Healthcare Leaders and Disruptors 2026, New York, NY: Wednesday, September 23 at 9:40am EDT
To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com
